Who
Marc Stapley
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Veracyte; Director, Glaukos; EVP Strategy & Corp Developmt, Illumina.
In numbers
- Trades disclosed
- 361
- Buys
- 1
- Sells
- 52
- Bought
- $980K
- Sold
- $44.6M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 20 Jan 2012
- Last trade
- 2 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 4 Sep 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code F | $394K8,782 at $44.88 | filing |
| 2 Sep 2026filed 4 Sep 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code F | $394K8,782 at $44.88 | filing |
| 4 Jun 2026filed 4 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code M | $5.1M138,051 at $36.60 | filing |
| 4 Jun 2026filed 4 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $6.9M138,051 at $50.12 | filing |
| 4 Jun 2026filed 4 Jun 2026 | VCYT Veracyteoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —138,051 at $0.00 | filing |
| 4 Jun 2026filed 4 Jun 2026 | VCYT Veracyteoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —138,051 at $0.00 | filing |
| 4 Jun 2026filed 4 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code M | $5.1M138,051 at $36.60 | filing |
| 4 Jun 2026filed 4 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $6.9M138,051 at $50.12 | filing |
| 2 Jun 2026filed 4 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code F | $431K9,012 at $47.80 | filing |
| 2 Jun 2026filed 4 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code F | $431K9,012 at $47.80 | filing |
| 28 May 2026filed 23 Jun 2026 | GKOS Glaukosoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,987 at $0.00 | filing |
| 28 May 2026filed 23 Jun 2026 | GKOS Glaukosoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,987 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | GKOS GlaukosMedical Devices | SEC FORM 4 Code A | —1,878 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | GKOS Glaukosoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,987 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | GKOS Glaukosoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,987 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | GKOS GlaukosMedical Devices | SEC FORM 4 Code A | —1,878 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —92,099 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —92,099 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $684K19,244 at $35.56 | filing |
| 4 Mar 2026filed 6 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $953K26,279 at $36.28 | filing |
News
Glaukos Expands Retinal Pipeline With RevOpsis Deal - Orange County Business JournalGKOS · ocbj.com · 19 Oct 2026Glaukos: IDose TR Plus Cataract Surgery Delivers Superior Eye Pressure Reduction In Phase 4 TrialGKOS · rttnews.com · 9 Oct 2026Glaukos Expands Retina Pipeline With Novel Biologic Licensing Deal; Stock DownGKOS · rttnews.com · 8 Oct 2026
0 headlines in the last 90 days name Marc Stapley; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.